Albumin + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
Sep 1, 2009 → Jun 1, 2013
NCT ID
NCT00990509About Albumin + Placebo
Albumin + Placebo is a phase 2 stage product being developed by Baxter for Intracerebral Hemorrhage. The current trial status is terminated. This product is registered under clinical trial identifier NCT00990509. Target conditions include Intracerebral Hemorrhage.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00990509 | Phase 2 | Terminated |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Edaravone Dexborneol + Placebo | Sun Pharmaceutical | Phase 2 | 52 |
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |